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Abstract
Activating KRAS mutations are found in approximately 20% of human cancers but no RAS-
directed therapies are currently available. Here we describe a novel, robust, KRAS syn-
thetic lethal interaction with the cyclin dependent kinase, CDK1. This was discovered using
parallel siRNA screens in KRASmutant and wild type colorectal isogenic tumour cells and
subsequently validated in a genetically diverse panel of 26 colorectal and pancreatic tumour
cell models. This established that the KRAS/CDK1 synthetic lethality applies in tumour cells
with either amino acid position 12 (p.G12V, pG12D, p.G12S) or amino acid position 13 (p.
G13D) KRASmutations and can also be replicated in vivo in a xenograft model using a
small molecule CDK1 inhibitor. Mechanistically, CDK1 inhibition caused a reduction in the
S-phase fraction of KRAS mutant cells, an effect also characterised by modulation of Rb, a
master control of the G1/S checkpoint. Taken together, these observations suggest that the
KRAS/CDK1 interaction is a robust synthetic lethal effect worthy of further investigation.
Introduction
KRAS, also known as the Kirsten rat sarcoma viral oncogene homolog protein (V-Ki-ras2), is a
member of the RAS superfamily [1, 2]. RAS proteins (HRAS, KRAS and NRAS) are small
GTPases that cycle between inactive guanosine diphosphate (GDP)-bound and active guano-
sine triphosphate (GTP)-bound conformations. RAS activity regulates a complex signalling
network including the RAF-MEK-ERK cascade, the phosphatidylinositol 3-kinase (PI3K)
pathway and the effector family of exchange factors for the RAL small GTPases [3–5]. Through
the combined action of these signalling pathways, expression of activated mutant RAS is
thought to promote several of the characteristics of malignant transformation. The KRAS
oncogene is one of the most frequently mutated genes in human cancer [6], being altered in
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approximately 20% of all human tumours [7]. Oncogenic forms of KRAS have profound effects
on signalling, which can result in a hyper-proliferative and anti-apoptotic phenotype [3, 8–10].
In addition, KRASmutations affecting amino acid position p.G12, cause resistance to EGFR
targeted therapy in colorectal cancer (CRC) [11, 12].
Because of the frequency of KRASmutations in human cancers considerable attention has
been paid to targeting this oncogene. These efforts include; (i) approaches that are based on
inhibiting signal transduction pathways that act downstream of KRAS, such as the use of MEK
inhibitors [13], (ii) the identification of synthetic lethal (SL) interactions with mutant KRAS
[14–21] and, (iii) direct small molecule inhibition of KRAS, an approach that exploits the pres-
ence of a mutant cysteine residue in KRAS mutant tumour cells with p.G12C mutations [22].
In the case of the SL approaches to targeting mutant KRAS, a considerable challenge has been
in discriminating those KRAS SL effects that are readily abrogated by other genetic/ epigenetic
changes in the tumour cell (soft SL effects) from those that are more resilient to these changes
(hard SL effects) [23].
Here, we describe the identification of a novel KRAS SL interaction involving the cyclin
dependent kinase, CDK1. This was identified using siRNA screens, was shown to operate in a
genetically diverse set of colorectal and pancreatic tumour cell models and was replicated with
small molecule inhibitors of CDK1, both in vitro and in vivo.
Materials and Methods
Cell lines
The LIM1215 and SW48 KRAS isogenic cell lines were generated and provided by Horizon
Discovery. The LIM1215 cell lines were cultured in RPMI supplemented with 10% FBS and
SW48 cell lines were grown in DMEM with 10% FBS. The C2BBe1, HT115, HT29, HT55,
LS411N, RKO, SNU-C1, SW1417, WiDr, DLD1, GP2D, HCT116, LOVO, LS513, SKCO1,
SW1116, SW480, SW620, T84, BxPC-3, HPAC, MIAPACA2, PANC1, PL45 and PL5 were
obtained from the American Type Tissue Collection and cultured according to the suppliers’
instructions. All cell lines were routinely confirmed as being mycoplasma negative using the
MycoAlert Kit (Lonza) throughout experimentation.
Reagents
AZD5438, RO-3306, AT7519, Dinaciclib and PD023309 were purchased from Selleck chemi-
cals. Antibodies targeting pan-RAS (Millipore), KRAS (Sigma), β-Actin, PARP-1 (F-2) (Santa
Cruz), CDK1, Phospho-CDK1 (Thr161), Rb and Phospho-Rb (Ser 807/811) (Cell Signaling
Technology), were employed in western blot.
High-throughput siRNA screening
A 384 well plate arrayed siRNA library targeting 784 genes (Dharmacon) was used (gene list
described in S1 Table). Each well contained a SMARTPool of four distinct siRNA species tar-
geting different sequences of the target transcript. Additional positive (siPLK1) and negative
(siCON1, siCON2 and AllStar (Dharmacon and Qiagen, respectively)) controls were also
added to each plate. The LIM1215 KRAS isogenic cell lines were plated in nine replica plates at
a density of 500 cells per well and reverse transfected using RNAiMax (Life Technologies).
After seven days cell viability in each well was estimated using a CellTitre-Glo assay. Data was
processed as described in [24]. Each screen was performed in triplicate. The luminescence
value from each well on each plate was first log2 transformed. To account for plate-to-plate var-
iation, we calculated the median effect in each plate and then normalized each well value
CDK1/KRAS Synthetic Lethality
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according to the plate median. Plate normalized values from triplicate screens were then com-
bined by the calculation of median values. To allow cell inhibitory effects to be compared
between cell lines and screens, we converted median plate normalized values to Z, or standard-
ized, scores, using the calculation Za = (xa−screen median) / variance of screen, where Za = Z
score for gene a, xa = plate normalized value for gene a. The screen median was calculated
according to the median value for all 784 siRNAs in the screen and the variance of the screen
was estimated by calculation of the Median Absolute Deviation (MAD).
High throughput screen siRNA revalidation
Revalidation of the siRNA screen hits was performed by deconvolution of the SMARTpool
into four distinct oligonucleotide species targeting four different sequences of the gene. Reverse
transfection and viability analysis were performed as described above. RNAi gene silencing was
also validated by western blot, where the cells were plated in 6-well plates and collected 48
hours after transfection for preparation of protein lysates and western blot analysis.
Protein analysis
Cells were lysed, electrophoresed and immunoblotted as described previously [25].
Cell cycle analysis
For cell cycle analysis by DNA content, cells were plated in 10 cm dishes and exposed to the
drug/siRNA in study. After the drug/siRNA exposure, cells were harvested, washed with PBS,
and fixed in 70% (v/v) ethanol. Cells were then washed twice in PBS and resuspended in 1 mL of
PBS containing 100 μL RNase A (Sigma) and 20 μL propidium iodide (PI) (Sigma). Total DNA
content was quantified and analyzed by flow cytometry on a Becton Dickinson fluorescence-acti-
vated cell scan cytometer and data was analysed using BD FACSDiva Software (BD Biosciences).
EdU Cell Proliferation Assay
The Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit was used for analyzing DNA rep-
lication in proliferating cells, according to the manufacturer’s instructions. EdU (5-ethynyl-2 0-
deoxyuridine) is a thymidine analog, which is incorporated into DNA during active DNA
synthesis.
Cells were incubated with 10 μL of a 10 mM solution of EdU in a 10 cm dish for 1h at 37°C,
5% CO2. After the incubation the cells were harvested and washed once with 3 mL of 1% (w/v)
BSA in PBS. The cells were then centrifuged and incubated with 100 μL of Click-iT fixative for
15 minutes at room temperature, protected from light. The cells were washed with 3 mL of 1%
BSA (w/v) in PBS, centrifuged, then resuspended in 100 μL of 1X Click-iT saponin-based per-
meabilization and wash reagent and incubated for 15 minutes. 0.5 mL of Click-iT reaction
cocktail was added to each tube and incubated for 30 minutes at room temperature, protected
from light. The cells were washed once with 3 mL of 1X Click-iT saponin-based permeabiliza-
tion and wash reagent, centrifuged and resuspended in 500 μL of 1X Click-iT saponin-based
permeabilization and wash reagent. DAPI staining was added for DNA staining. Standard flow
cytometry methods were used for determining the percentage of S- phase cells in the popula-
tion and DNA content.
DNA sequencing
Genomic DNA was isolated from the cell lines using the Puregene—blood, cell and tissue kit
(Qiagen), according to manufacturer’s instructions, eluted in 20 μL H2O and stored at -20°C.
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DNA concentration was measured using a spectrophotometer measuring the UV absorbance
at 260 nm. Typically PCR reactions contained 10–100 ng DNA, and were done in 50 μL reac-
tion volume, using Expand High Fidelity PCR system (Roche). PCR conditions were as follows:
95°C for 5 min; thirty cycles of 94°C for 1 min, 55°C for 1 min, 72°C for 45 sec, followed by a
single cycle at 72°C for 5 min and 4°C thereafter. PCR products were purified from agarose gel
using QIAquick Gel extraction Kit (Qiagen). Cycle sequencing was carried out using BigDye
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA) with an initial
denaturation at 95°C for 1 min, then 25 cycles at 96°C for 10 sec, 50°C for 5 sec, and single
cycle at 60°C for 4 min. Sequencing products were purified using DyeEx 2.0 spin protocol for
Dye-Terminator removal (Qiagen), and analysed using the ABI PRISM 377 DNA sequencer
(Perkin Elmer). The data was analysed using Sequencher 4.8 software.
Cell viability assays
Cells were plated in 96-well (250–1000 cells/well (depending on the cell line)) plates in 80 μL.
After 24 hours, drug or vehicle (DMSO) dilutions in media were added to the cells to make a
total volume of 100 μL. Cells were left exposed to drug for five days. Cell viability was assessed
using the luminescent CellTiter-Glo reagent (Promega) whereby 50 μL of reagent diluted 1:4 in
PBS was added to each well, which was shaken for 10 minutes at room temperature according
to the manufacturer’s protocol. Luminescence was measured using the Victor X5 Multilabel
plate reader (Perkin Elmer).
RAS activation assay
Activated RAS was measured using a RAS activation assay kit according to manufacturer’s
instructions (Millipore). RAS alternates between an active, GTP-bound state and an inactive,
GDP-bound state. RAS family effector proteins specifically recognize the GTP-bound form of
RAS. This is exploited experimentally to determine the levels of RAS protein activation. The
assay uses the RAS-binding domain (RBD) of the RAS effector kinase c-RAF, which binds spe-
cifically to the GTP-bound form of RAS proteins. The RAF-RBD is conjugated with agarose
beads, which allows the precipitation of the RAF-RBD/GTP-RAS complex. For the RAS pull-
down assay, 500 μg of whole cell lysates (freshly collected) were incubated with the RAF-RBD-
agarose beads for 45 min at 4oC with gentle agitation. After washing the agarose beads, the
amount of GTP-RAS was quantified by western blotting of purified samples with a mouse
monoclonal antibody recognizing all three isoforms of RAS. MCF7 and HeLa cells were used
as controls of the experiment. HeLa cells were also stimulated with 50 nM EGF as a positive
control.
In vivo experiments
All mouse work was carried out in accordance with the Institute of Cancer Research (ICR)
guidelines and with the UK Animals (Scientific Procedures) Act 1986 and approved by the ICR
Animal Welfare and Ethical Review Body. Animals were housed in IVC type cages (Opti-
mouse–Animal Care Systems Inc.), which were maintained under negative airflow. Mice were
companion held and a density commensurate with the UK Home Office Code of Practice for
the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes. Animals
were provided with Corncob bedding, nesting material and environment enrichment. All ani-
mals were fed Ad-libitum with Lab diet 5002 rodent diet. Water was filtered and chlorinated.
Animal holding rooms were maintained within the parameters recommended in the Home
Office Code of Practice with temperatures being 21°C +/- 2 degrees, Humidity 55% +/- 10%
and a light cycle of 12 hours dark/light. Animals were monitored daily by facility staff for basic
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husbandry requirements and signs of ill health. Study animals were also monitored by AK and
SCC.
For assessment of the in vivo efficacy of AZD5438, 5x106 of SW620 cells, or SW48 KRAS
WT or p.G12V isogenic cells were injected into the flank regions of female athymic Balb/C
mice, twenty mice per cell line (Harlan Laboratories). In the drug arm ten mice were treated
once daily with AZD5438 by oral administration starting immediately after tumour establish-
ment at a dose of 20mg/kg and ten mice were treated once daily with vehicle (0.5% methylcel-
lulose) in the control arm.
Tumour growth was monitored at least twice a week, taking two-dimensional measure-
ments with callipers. The mice were monitored daily for toxicity, and culled when the maxi-
mum tumour volume was reached (1.2 cm3) or if there was more than 20% weight loss.
Tumour volume was calculated using the formula (LW)(SQRT(LW))(π/6) (L, length, W,
width, π, pi), where length represented the longer diameter of an asymmetrical tumour.
All procedures were performed according to the project licence number 70/6367 and under
the regulations of the Animals (Scientific Procedures) Act 1986. Mice were sacrificed by the
Schedule 1 methods of cervical dislocation or decapitation according to the UK Animals Act
1986.
Results
Synthetic lethal screening in an isogenic KRAS mutant tumour cell
system
To identify candidate KRAS synthetic lethal interactions, we first generated and validated an
isogenic cell line system to model the presence or absence of oncogenic KRASmutations. We
selected the KRAS wild type (WT) colorectal tumour cell line, LIM1215 as a model [26] and
used AAV gene targeting to introduce one of three different oncogenic mutant KRAS alleles
(enconding p.G12D, p.G12S and p.G12V) into the endogenous KRAS gene at position glycine
12 [27] (Fig 1A and S1 Fig). Replacement of one of the endogenous WT KRAS alleles with a
mutant allele caused constitutive KRAS activation in all three cases, as assessed by measuring
levels of active GTP-RAS (Fig 1B and S2A Fig). We also confirmed KRAS addiction in the
KRASmutant cell lines, by demonstrating cell growth inhibitory effects of siRNAs targeting
KRAS (Fig 1C and 1D), after demonstrating that KRAS siRNA duplexes caused KRAS silenc-
ing (Fig 1E and S2B Fig).
We used parental LIM1215 KRASWT (KRASWT/WT) cells and of KRASWT/G12D, KRASWT/G12S
and KRASWT/G12V models in parallel siRNA screens to identify candidate synthetic lethal effects.
For each genotype, we siRNA screened two independently derived clones. A LIM1215 clone
encompassing a control targeting vector (LIM1215neo) was also screened in parallel. As a screening
library, we used a 384 well plate arrayed siRNA library targeting 853 genes, predominantly protein
kinase encoding genes. We focused on protein kinases given their inherent tractability as drug tar-
gets as well as their involvement in a wide range of intracellular signalling processes. Cells were
reverse transfected with siRNA on day 0, and cell viability was estimated six days later using Cell
Titre Glo reagent. In total we carried out two biological replicate screens for each clone, with each
biological replicate encompassing three technical replica screens (Fig 2A). After assessing the qual-
ity of each screen by the calculation of Z’ values and Spearman rank correlation between replicates,
we estimated the effect on cell inhibition of each siRNA in each clone and quantified these effects
by calculating robust Z scores for each siRNA (Fig 2B and S3 Fig). The entire screening dataset is
detailed in S1 Table.
To identify candidate KRAS synthetic lethal effects, we compared Z scores for each siRNA
in KRASmutant vs. WT clones. We used robust statistical thresholds to identify the most
CDK1/KRAS Synthetic Lethality
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Fig 1. Characterization of LIM1215 isogenic cell lines. (A) Schematic of KRAS isogenic cell lines generation. KRASmutations were introduced into the
parental cell lines via r-AAV-mediated homologous recombination. A general structure of the targeting construct is represented. The resulting mutant KRAS
allele is expressed from its endogenous promoter. The Neo cassette is removed from the genome of the targeted cells by Cre recombinase-mediated
CDK1/KRAS Synthetic Lethality
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profound synthetic lethal effects, namely a median Z score across the p.G12 mutant cell lines
(KRASWT/G12D, KRASWT/G12S and KRASWT/G12V) of -2 (approximately equal to a p< 0.05
effect) and a median Z score in the control, non-KRAS mutant lines of -1. Using these
thresholds we identified six candidate KRAS SL genes; Cyclin-Dependent Kinase 11B
(CDK11B), Integrin-Linked Kinase (ILK), Casein Kinase 1, Gamma 1 (CSNK1G1), Cell Division
Cycle 73 (CDC73), Cyclin Dependent Kinase 1 (CDK1) and General Transcription Factor IIH,
Polypeptide 1, 62kDa (GTF2H1) (Table 1 and Fig 2B).
Identification of robust KRAS synthetic lethality effects
One of the challenges in the identification and validation of synthetic lethal targets in cancer is
distinguishing “hard” synthetic lethal effects that are relatively resistant to other genetic or epi-
genetic changes, from “soft” synthetic lethal effects that are readily abrogated by such changes
[23]. Our intention was to identify relatively robust, hard synthetic lethal effects. We therefore
assessed each of the six candidate KRAS SLs identified in the LIM1215 screen in a second
KRAS isogenic system consisting of a second colorectal tumour cell model, SW48, in which
KRAS mutant alleles were also introduced by AAV gene targeting. From a parental SW48
(KRASWT/WT) clone, we generated isogenic KRASWT/G12D, KRASWT/G12S, KRASWT/G12V and
KRASWT/G13D clones and assessed RAS activation in these clones (Fig 3A and S4A Fig) as well
as KRAS addiction (Fig 3B), as before.
Using this second isogenic system, we assessed the effect of six candidate KRAS SLs using
siRNA gene silencing. From these six candidates only Cyclin-Dependent Kinase 1 (CDK1) vali-
dated, as the CDK1 siRNA gave a more profound effect in the SW48 KRAS mutant cells than
WT cells (Fig 3C). We did however note that CDK1 siRNA, whilst having a greater effect in
KRAS mutant cells, did also elicit some level of cell inhibition in SW48 KRASWT cells, and
therefore CDK1 may be regarded as synthetic sick with KRAS, rather than synthetic lethal.
CDK1, also known as CDC2, is a cyclin dependent kinase (CDK) implicated in G2/M transition
and progression through mitosis. CDK1 is activated by A-type cyclins in late G2, an event that
drives mitosis [28, 29]. While CDK1 has been primarily implicated in the G2/M transition, a
number of studies have demonstrated that CDK1 is also involved in G1/S transition [30–32].
CDK1 binds interphase (D-type and E-type) cyclins, and these interactions are increased in
cells deficient in interphase related CDKs, such as CDK2 or CDK4. Therefore, CDK1 may be
crucial for the regulation of growth-inducing transcription as well as DNA replication and
repair [30–33].
Having established that multiple independent CDK1 siRNA duplexes caused CDK1 silenc-
ing and KRAS selectivity (Fig 3C and 3D and S4B Fig), we assessed cell growth inhibition in a
panel of 20 genetically diverse colorectal tumour cell line models transfected with multiple dif-
ferent CDK1 siRNAs (S2 Table). To confirm KRAS addiction in each cell line, we determined
the cell growth inhibitory effects of KRAS depletion (Fig 4A and 4B). Next, we compared the
growth inhibitory effects of CDK1 siRNA in the KRASmutant (n = 10) and WT cohorts
excision. AAV, adeno-associated virus; ITR, inverted terminal repeat; Neo, geneticin-resistance gene; P, SV40 promoter; triangles, loxP sites
(Figure adapted from [27]). (B) RAS activation status of LIM1215 KRAS isogenic cell lines. Western blot showing active RAS (RAF1 GTP-bound) levels for
LIM1215 KRAS isogenic cell lines. The RAF1 RAS binding domain (RBD) was used to precipitate GTP-RAS. The RAS activation status was tested for each
clone with mutated KRAS. Precipitated RAS-GTP was detected by western blot using anti-RAS antibody. As a positive control, HeLa cells (RAS wild-type)
were stimulated with epidermal growth factor (EGF) to activate the RAS pathway. HeLa and MCF7 cells (unstimulated) were used as negative controls. Total
lysates were also immunoblotted with anti-β-Actin antibody as loading control. (C) and (D) KRAS dependence in the LIM1215 KRAS isogenic cell line
models, obtained from the HT siRNA screen described in Fig 2. Bar graph of KRAS siRNA Z-score values across the LIM1215 KRASWT and mutant
isogenic cell lines, C and D respectively. KRAS dependence was greater in the cell lines carrying KRASmutations than in WT cells. Error bars represent
SEM from three independent experiments. (E) Western blot of KRAS in SW48 cells expressing KRAS-specific siRNAs. Multiple KRAS siRNA oligos and a
pool efficiently suppressed KRAS expression showing that the siRNAs were on-target.
doi:10.1371/journal.pone.0149099.g001
CDK1/KRAS Synthetic Lethality
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Fig 2. Identification of CDK1 as a KRAS synthetic lethality using functional genomic screens in the LIM1215 KRAS isogenic models. (A) Schematic
describing the screen format. LIM1215 cells plated in 384 well plates were transfected with siRNA. Each transfection plate contained 300 experimental
siRNAs supplemented with wells of non-targeting siCONTROL (siCON) and siRNA targeting PLK1 (positive control). Transfected cells were divided into
CDK1/KRAS Synthetic Lethality
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(n = 10). We found that although CDK1 siRNA did inhibit multiple KRASmutant models it
also had inhibitory effects in KRASWTmodels, HT29, WiDr, LS411N, SW1417 and RKO (Fig
4C and 4D), an observation inconsistent with the KRAS SL effects observed in the isogenic sys-
tems (Fig 3C). However, a more in-depth analysis of this data indicated that those KRASWT
models that were sensitive to CDK1 siRNA had oncogenic p.V600E BRAFmutations (Fig 4E).
BRAF is a KRAS effector and part of the mitogen-activated protein kinases (MAPK) RAS--
RAF-MEK-ERK signalling cascade. Upon KRAS activation, BRAF is recruited to the cell mem-
brane, where its phosphorylation status is altered, an event that subsequently causes MEK1/2
and ERK activation [3].
Reanalysis of the colorectal cell line dataset suggested that CDK1 silencing was indeed selec-
tive for the KRASmutant/ BRAFWT cohort compared to the KRASWT/BRAFWT cohort
(p<0.01, Student’s t-test, Fig 4F) and that CDK1 siRNA was also selective for the KRASWT/
BRAFmutant models compared to KRASWT/BRAFWTmodels (p<0.05, Student’s t-test, Fig
4G). It seems possible that both KRAS and BRAF drive a shared process or series of effects that
induce CDK1 synthetic lethality. We also noted that there was some variation in the inhibitory
effect of CDK1 siRNA across the panel of KRASmutant/ BRAFWT cohort. This might suggest
that in addition to KRAS being a determinant of CDK1 siRNA sensitivity, additional determi-
nants of sensitivity might also enhance or decrease the extent of synthetic lethality.
We also assessed the KRAS/CDK1 SL in cell models of pancreatic ductal adenocarcinoma
(PDAC), a disease where where somatic KRASmutations are prevalent in approximately 90%
of cases [34]. We found that in a cohort of six PDAC cell line models, the five KRAS mutant
models (S2 Table) were not only more sensitive to KRAS siRNA but also more sensitive to
CDK1 siRNA than the KRASWT BxPC3 PDAC model (Fig 4H and 4I).
Chemical inhibition of CDK1 causes KRAS synthetic lethality in vitro and
in vivo
To assess the therapeutic potential of these observations, we assessed the sensitivity of KRAS
mutant models to small molecule inhibitors of CDK1. Here we used two chemically distinct
inhibitors, RO-3306, a CDK1 inhibitor [35] and AZD5438, a CDK1/2 and 9 inhibitor [36]. We
found both inhibitors were KRAS selective in the SW48 isogenic system (Fig 5A and 5B, S3
Table), validating the siRNA results. Further assessment of CDK1 inhibitor sensitivity in panels
of non-isogenic CRC and PDAC cell lines showed a KRAS mutant selective response after
AZD5438 exposure. For example, the CRC mutant cell lines, SW620 and HCT116, showed a
three replica plates. Cell viability was assessed after six days using CellTiter-Glo Luminescent Cell Viability Assay (Promega). (B) Heatmap of siRNA z-
scores for 15 screens used in the analysis. The rows of the heatmap correspond to siRNAs and are ordered by the difference in the KRASmutant and non-
mutant group median z-scores. The heatmap inset shows the six siRNAs selected for andditional analyses. These siRNAs were selected because they
caused reduced viability in the KRASmutant isogenic models (median z -2) but not in the WT and neo cell lines (median z -1).
doi:10.1371/journal.pone.0149099.g002
Table 1. CandidateKRAS synthetic lethal genes identified in LIM1215 KRAS isogenic cell lines siRNA
screens. The table shows the median Z scores for the KRASWT and mutant cells and the respective Delta
median Z scores.
Gene Symbol Mutant median Z scores WT median Z scores Delta median Z scores
CDK11B -2.59 -0.74 -1.85
ILK -2.39 -0.61 -1.79
CSNK1G1 -2.31 -0.79 -1.53
CDC73 -2.09 -0.64 -1.46
CDK1 -2.11 -0.80 -1.32
GTF2H1 -2.05 -0.86 -1.19
doi:10.1371/journal.pone.0149099.t001
CDK1/KRAS Synthetic Lethality
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significant difference in sensitivity when compared to the KRASWT cells, HT55, C2BBe1,
P<0.0001, two-way ANOVA (Fig 5C, S3 Table). The PDAC KRAS mutant cell lines, HPAC,
PL5 and PL45, also showed a significant difference in sensitivity when compared to the KRAS
WT cells, BxPC3, P<0.001, P<0.0001 and P<0.01, respectively, two-way ANOVA (S5A Fig,
S3 Table). Also we found that the KRASWT/BRAFmutant models RKO and LS411N showed
sensitivity to as well as sensitising to CDK1 siRNA results previously discussed (S5B Fig).
These results suggest that colorectal BRAFmutant cells, together with the KRASmutant cell
lines, are sensitive to CDK1 inhibition.
KRASmutant tumour cells exhibit elevated CDK1 activity and exhibit an
S phase entry defect upon CDK1 inhibition
To investigate the molecular basis of the KRAS/CDK1 SL, we assessed the extent of CDK1 pro-
tein expression and phosphorylation using western blot analysis. We found the extent of
Fig 3. Validation of the CDK1 hit from the LIM1215 siRNA screen in SW48 isogenic cell lines. (A) GTP-RAS assay showing the RAS activation status of
SW48 KRAS isogenic cell lines. (B) KRAS dependence in the SW48 KRAS isogenic cell lines (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, Student’s t-
test for comparison between each KRASmutant and theWT cell lines). (C) CDK1-specific siRNAs suppress CDK1 expression. Cell viability after CDK1
depletion in SW48 isogenic KRAS cell lines (ns, not statistically significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, Student’s t-test for comparison
between each KRASmutant and theWT cell lines). Error bars represent SEM from three independent experiments. (D) Western blot of CDK1 in SW48
parental cells expressing CDK1-specific siRNAs.
doi:10.1371/journal.pone.0149099.g003
CDK1/KRAS Synthetic Lethality
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Fig 4. Effects of CDK1 depletion in non-isogenic KRASmutant cell models. (A) and (B) Waterfall and scatter plots, respectively, of a panel of non-
isogenic colorectal cell lines showing a statistically significant difference in surviving fraction in response to KRAS depletion by siRNA between the KRASWT
(black) and mutant (pink) cell lines (P<0.0001, Student’s t-test for comparison between KRASmutant andWT cell lines). (C) and (D) Waterfall and scatter
CDK1/KRAS Synthetic Lethality
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CDK1 phosphorylation at Thr161 to be enhanced in KRASmutant cells compared to WT cells
in the SW48 KRAS isogenic model, PDAC and CRC non-isogenic tumour cell lines (Fig 6A–
6C and S6 and S7 Figs). CDK1 phosphorylation at Thr161 is caused by the activity of CDK-
plots, respectively, showing the surviving fractions of a panel of non-isogenic CRC cell lines after CDK1 depletion by siRNA. Black bars represent KRASWT
cell lines and pink bars represent KRASmutant cell lines (ns, not statistically significant, Student’s t-test for comparison between KRASmutant andWT cell
lines). (E) Waterfall plot of the same CRC cell line panel as described in 4C, but with the KRASWT cells divided into KRASWT/BRAFWT (black), KRASWT/
BRAFmutant (green). (F) Scatter plot of the panel of CRC non-isogenic cell lines, without the KRASWT/BRAFmutant cells, showing that the difference
between the KRASmutant (pink) andWT (black) cells to CDK1 depletion by siRNA is statistically significant (**P>0.01, Student’s t-test for comparison
between KRASmutant andWT cell lines.). (G) Scatter plot demonstrating a statistically significant difference in survival between KRASWT/BRAFWT (black)
and KRASWT/BRAFmutants (green) after CDK1 depletion (*P>0.05, Student’s t-test for comparison between BRAFmutant andWT cell lines.). (H)
Waterfall plot of pancreatic cell lines showing that the KRASmutant cells (pink) were significantly more sensitive to KRAS depletion by siRNA than the KRAS
WT cells (black) (***P<0.001, Student’s t-test for comparison between each KRASmutant cell lines and theWT cell line). (I) Waterfall plot of pancreatic cell
lines showing that the KRASmutant cells (pink) were significantly more sensitive to CDK1 depletion by siRNA than the KRASWT cells (black) (***P<0.001,
Student’s t-test for comparison between each KRASmutant cell lines and theWT cell line). Surviving fractions normalized to siControl1 transfected cells.
Error bars represent SEM from three independent experiments.
doi:10.1371/journal.pone.0149099.g004
Fig 5. CDK inhibitors sensitivity profile in SW48 KRAS isogenic cell lines. (A) Exposure of SW48 isogenic cell lines to RO-3306 in a fifteen-day colony
formation assay. (B) Exposure of SW48 isogenic cell lines to inhibitor AZD5438, in a fifteen-day colony formation assay. (C) Drug-dose response curves of
CRC cells after AZD5438 exposure in a fifteen-day colony formation assay. ****P<0.0001, Two-way ANOVA. Error bars represent SEM of three technical
replicates. All the experiments were performed two independent times with three technical replicates.
doi:10.1371/journal.pone.0149099.g005
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Fig 6. (A—C). CDK1 phosphorylation levels in KRASmutant andWT cells as shown byWestern blot analysis of total cell protein lysates from SW48 KRAS
isogenic (A), non-isogenic pancreatic tumour cell lines (B) and non-isogenic colorectal cell lines (C). Western blots were probed for CDK1 (pThr161 CDK1
and total CDK1). β-actin detection was used as a loading control. (D and E) Bar graphs illustrating the percentage of cells in G1, S and G2/M cell cycle
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activating kinase (CAK), which leads to activation of CDK1 and can improve its binding to
cyclins [37]. We therefore concluded that there was an enhanced level of CDK1 activity in
KRAS mutant cells.
CDK1 regulates several steps of cell cycle progression [32]. Variations in levels of activated
CDK1 could conceivably cause differences in cell cycle progression and timing. We decided to
examine the cell cycle profile of SW48 KRAS p.G12V mutant and WT cells either in the pres-
ence or absence of CDK1 inhibitor. In the absence of CDK1 inhibition KRAS p.G12V mutant
cells showed a modest increase in the proportion of cells in G1 when compared to WT cells
(after 48h, 65.9% versus 55.6%, respectively). This difference was enhanced when cells were
exposed to AZD5438 (G1 fraction in p.G12V KRAS mutant cells exposed to 0.3 μM = 87.7%
compared to 68.7% for similarly treated WT cells). Concomitantly, we noticed a significant
reduction in the proportions of KRAS p.G12V mutant cells in the S- and G2/M phases when
compared to WT cells after cells were exposed to AZD5438 (S fraction in p.G12V KRAS
mutant cells exposed to 0.3 μM = 6% compared to 16.2% for similarly treated WT cells,
p = 0.034, Student’s t-test) (Fig 6D and 6E, S8 Fig).
As the proportion of cells in S-phase after exposure to AZD5438 was lower in the KRAS p.
G12V cells than in the WT cells, we examined S phase progression by measuring DNA synthe-
sis using the Click-iT Plus 5-ethynyl-2'-deoxyuridine (EDU) assay. In this assay, the fluores-
cently labelled thymidine analogue EDU is incorporated into newly synthesized DNA, an event
that can be monitored by measuring fluorescence [38]. DNA content analysis together with
EDU analysis suggested that AZD5438 caused a significant defect in S-phase progression in
KRASmutant cells when compared to both untreated mutant andWT cells (Fig 6F–6H).
These results suggested that the inhibition of CDK1 by AZD5438 caused a disruption in DNA
synthesis in the KRASmutant cells, an effect that was not as profound in KRASWT cells.
So that cells can proceed into S-phase, Retinoblastoma protein (Rb) is phosphorylated by
either CDK1 or CDK2 at Ser807 and Ser811. This post translational modification inactivates
Rb and facilitates cell cycle progression [39]. We therefore determined whether the enhanced
G1 fraction and reduction in S-phase cells caused by AZD5438 exposure in KRAS mutant cells
was also associated with differences in Rb phosphorylation (Fig 6I). In KRAS p.G12V mutant
cells, Rb Ser807 and Ser811 phosphorylation were both reduced by AZD5438 exposure. In
KRASWT cells, Rb phosphorylation was maintained in the face of AZD5438 exposure (Fig 6I
and S9A Fig). Taken together, these findings suggested that KRAS p.G12V isogenic cells have a
delay in entering S-phase and become arrested in G1-phase upon exposure to AZD5438.
We further assessed the mechanism of cell inhibition caused by AZD5438. We found that a
high, non KRAS selective concentration of AZD5438 caused PARP cleavage in both KRASWT
and mutant cells, but a KRAS selective concentration of AZD5438 caused apoptosis in the
KRAS mutant cell line but not in the KRAS model (Fig 6J and S9B Fig). This suggested that the
KRAS selective effect of AZD5438 might be caused by G1 arrest followed by apoptosis.
phases in SW48 KRASWT or p.G12V mutant cell lines after AZD5438 exposure. SW48 KRASWT (D) and p.G12V (E) were exposed to 0.3 μMAZD5438 or
DMSO for 16, 24 and 48 hours after which cell cycle profiles were assessed by propidium iodide (PI) staining and flow cytometry. The KRAS p.G12V mutant
cells showed a decrease in S and G2-fractions after exposure to AZD5438 when compared to control (DMSO) treated cells and to KRASWT cells (AZD5438
and DMSO). (F—H) DNA synthesis in SW48 KRASWT and p.G12V cell lines after AZD5438 exposure. (F) and (G) 5-ethynyl-2'-deoxyuridine (EDU)/ PI
FACS plots in SW48 KRASWT (F) and p.G12Vmutant cells exposed to AZD5438 0.3 μM and 0.75 μM, or DMSO for 24 and 48 hours. After AZD5438
exposure, EDU/PI profiles were assessed by flow cytometry. EDU stained cells are represented in blue. (H) Bar graph illustrating the percentage of cells
stained with EDU over time for both SW48 KRASWT and p.G12Vmutant cells. (I) Western blot illustrating the phosphorylation of Retinoblastoma protein
(pRb) in SW48 KRASWT and p.G12V mutant cell lines after AZD5438 exposure. Cells were exposed to AZD5438 for two hours after which total cell lysates
were generated and western blotted as shown. Detection of β-Actin was used as a loading control. The levels of Rb phosphorylation on Ser807/811 were
decreased in the KRAS p.G12V cells when compared to the WT cells, after AZD5438 2 hours exposure. (J) Western blot illustrating PARP1 cleavage in
SW48 KRASWT and p.G12V mutant cells after 72h of AZD5438 exposure. Cells were exposed to AZD5438 for two hours after which total cell lysates were
generated and western blotted as shown. Exposure to camptothecin was used as a positive control.
doi:10.1371/journal.pone.0149099.g006
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Synthetic lethality of other CDK inhibitors with KRAS
The druggable nature of CDKs, along with the recurrent dysregulation of CDK activity in
human cancer, has led to intensive efforts to develop selective CDK inhibitors [40]. CDK4 has
already been proposed as being synthetic lethal with KRAS [17] and here we identified CDK1
as a KRAS SL partner, reinforcing the potential of cyclin dependent kinases as KRAS synthetic
lethal targets.
In order to identify whether other small molecule CDK inhibitors elicited the same KRAS
selective effects as AZD5438, we assessed the tumour cell inhibitory effects of a range of CDK
inhibitors: (i) AT7519, a CDK1/2/4/5/9 inhibitor [41]; (ii) dinaciclib, a CDK1/2/5/9 inhibitor
[42]; and as a control (iii) PD023309, a CDK4/6 inhibitor [43], in a panel of CRC non-isogenic
tumour cell lines (Fig 7 and S10 Fig). AT7519, a CDK1/2/4/5/9 inhibitor [41], showed the
greatest selectivity for KRAS mutant tumour cells. The average KRAS mutant selectivity of
AT7519 was 6.5-fold compared to WT cells (p = 0.0083, two-way ANOVA) (Fig 7A, S10A Fig,
S4 Table). Dinaciclib, a CDK1/2/5/9 inhibitor, also showed KRAS selectivity although this was
less profound than for AT7519 (p = 0.0155, two-way ANOVA) (Fig 7B, S10B Fig, S4 Table).
Finally, PD023309, a CDK4/6 inhibitor, did not show KRAS selectivity in the CRC tumour cell
lines tested (p = ns, two-way ANOVA) (Fig 7C, S10C Fig, S4 Table), although Barbacid and
colleagues have previously demonstrated that PD023309 inhibits the proliferation of KRAS p.
G12V-induced non-small cell lung cancer (NSCLC) cells [17].
CDK inhibition reduces tumour growth in KRASmutant xenografts
On the basis of the in vitro selective effects of AZD5438 on KRAS mutant cells, we assessed in
vivo efficacy of AZD5438. We xenografted SW620 (KRAS p.G12V) colorectal tumour cells into
immunocompromised mice and once tumours had established, we treated animals with
AZD5438. Specifically, animals with established SW620 tumours (80 mm3) were randomized
into one of two cohorts and treated with either 20 mg/kg/day AZD5438 or vehicle (n = 10 in
each cohort) (Fig 8). The growth of SW620 xenografts, was clearly inhibited by AZD5438 treat-
ment with some mice exhibiting complete tumour eradication (Fig 8A). SW620 xenografted
mice, treated with AZD5438 also showed a survival advantage compared to vehicle treated
mice (Fig 8B). Moreover, the weight of tumours in the AZD5438 treated mice cohort was in
general 60% less than in vehicle treated mice (p< 0.01, t-test) (Fig 8C), suggesting that
AZD5438 could inhibit a KRAS mutant tumour in vivo. To confirm that this in vivo efficacy
effect might be KRAS selective, we assessed the ability of AZD5438 to inhibit established xeno-
grafts from either KRASWT or p.G12V mutant SW48 cells (S11 Fig). Whilst AZD5438 had no
effect on KRASWT xenografts, we observed a statistically significant inhibition of KRAS
mutant xenografts compared to vehicle treatment (p = 0.0023, one-way ANOVA).
Discussion
Here, we describe a series of experiments aimed at identifying novel dependencies in KRAS
mutant tumour cells. Using genetic screens in LIM1215 KRAS isogenic cell lines we identified
novel KRAS synthetic lethal effects, including CDK1. One weakness of the HT screen might be
the use of engineered models of KRAS mutation, rather than the use of models with naturally
occurring KRAS mutations. It is possible that these engineered models do not fully replicate all
of the KRAS synthetic lethal effects found in real human tumours. However, we do note that
we also observed the KRAS selective effect of CDK1 inhibition in tumour cell lines with natu-
rally occurring KRAS mutations (Fig 4, Fig 5 and Fig 7). CDK1 was validated using a different
KRAS isogenic cell model (SW48) as well as a series of non-isogenic CRC and PDAC tumour
cell models. This analysis suggested that the CDK1/KRAS synthetic lethal effect was not
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Fig 7. Response to three second-generation CDK inhibitors in CRC cell lines. (A) AT7519, (B) dinaciclib
and (C) PD023309 median of drug-dose response curves of KRASWT and mutant cells from a five-day cell
viability assay to assess the KRAS selectivity of the CDK inhibitors in ten colorectal cell lines, four KRASWT
(black) and six mutant (pink) cell lines. (ns not-significant, Two-way ANOVA) Experimental conditions were
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restricted to isogenic systems but also operated in a variety of different, genetically diverse,
KRAS mutant tumour cells. One priority in identifying SL effects is to discriminate SLs that are
easily abrogated by additional genetic and epigenetic alterations (soft SLs) from those that are
somewhat more resistant to these changes (hard SLs) [23]. The analysis in the non-isogenic
tumour cell panel suggested that the CDK1/KRAS SL was a relatively hard synthetic lethal
effect. CDK1 forms active complexes with A-, B-, E-, and D-type cyclins [30], as part of its criti-
cal role in cell cycle progression. Inhibition of CDK1 with AZD5438, led to a marked reduction
in the proportion of cells in S and G2/M phases of the cell cycle in KRAS mutant cells. This was
accompanied by an increased in the proportion of cells in G1. Moreover, western blotting
revealed that AZD5438 decreased Rb phosphorylation levels in KRAS mutant cells compared
repeated in triplicate. Error bars represent SEM. Only AT7519 and dinaciclib showed KRAS selectivity in the
CRC cell lines.
doi:10.1371/journal.pone.0149099.g007
Fig 8. In vivo efficacy of AZD5438 in SW620 cell xenografts. KRASmutant xenografts were treated with vehicle (DMSO in black) or AZD5438 (20mg/kg/
day (in pink)). (A) Mean of increase in tumour volume relative to initial tumour volume. A one-way ANOVA was performed to compare both arms and the
difference in the SW620 xenografts was statistically significant (p = 0.017). (B) Survival curves showing a statistically significant difference between the
treated and vehicle arms, where the mice in the drug arm had an increase in overall survival using a Log-rank Mantel-Cox test (p = 0.0018 in SW620
xenografts). (C) Average final tumour weight. There is a significant difference between the vehicle and treatment arms (**p < 0.01, t-test). Error bars
represent SEM. (D) Photograph of a mouse treated with AZD5438, where the tumour disappeared completely, after 37 days of treatment.
doi:10.1371/journal.pone.0149099.g008
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to KRASWT cells. As cells require hyperphosphorylation of Rb to pass the restriction point in
G1 prior to entering S-phase, the reduction in Rb phosphorylation could provide an explana-
tion as to the cell cycle arrest, which could be a possible cause for the reduced proportion of
KRAS mutant cells in S-phase [39]. We determined the mechanism of cell inhibition to be apo-
ptosis, where western blotting showed increased PARP cleavage in the SW48 p.G12V cells. We
also assessed the anti-tumour effect of AZD5438 on human tumour xenografts to access the
KRAS selectivity of this compound in an in vivo setting. These experiments were performed in
immunocompromised mice with SW620 cell together with SW48 KRAS isogenic p.G12V and
WT cells xenografts, and have confirmed the KRAS selective inhibitory effect of AZD5438,
supporting the in vitro results. Overall the results from this experiment suggested disease stabi-
lisation after AZD5438 treatment, but in some cases complete tumour inhibition was observed.
Already a number of other synthetic lethal interactions involving cyclin dependent kinases
have been proposed. Perhaps the most notable synthetic lethal interaction involving CDK1
described to date is between CDK1 and the oncogenic transcription factor, MYC [44]. In this
particular case, MYC overexpressing tumour cells appear to be reliant upon the activity of the
inhibitor of apoptosis protein (IAP), BIRC5 (survivin) a CDK1 target [44]. This particular syn-
thetic lethality can be elicited in triple negative breast tumour cells using the clinical
CDK1,2,5,9 inhibitor dinaciclib [45]. As well as providing a potential route to targeting MYC
driven tumours, CDK1 inhibition has also been proposed as a route to causing chemosensitiv-
ity, enhancing the effects of PARP inhibitors [46] as well as PI3-kinase inhibitors [47]. Here we
show a KRAS/CDK1 synthetic lethality that can be elicited with small molecule CDK1 inhibi-
tors might also be added to the list of potential utilities for small molecule CDK inhibitors in
cancer.
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